| ABTI-PHARMA-LIMITED |
ABTI-PHARMA-LIMITED |
62%
|
NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS Company Background Protagenic Therapeutics, Inc. (“we,” “our,” “Protagenic” or “the Company”), formerly known as Atrinsic, Inc., is a Delaware corporation… |
| ALINOVA-BIOSCIENCES-LTD |
ALINOVA-BIOSCIENCES-LTD |
62%
|
anies such as Apex Molecular Ltd. to synthesize and purify these compounds for their pharmaceutical development programs. ● Acquisition of intellectual property from Alinova Biosciences Ltd. ● Contin… |
| ALTEROLA-BIOTECH-INC |
ALTEROLA-BIOTECH-INC |
62%
|
NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS Company Background Protagenic Therapeutics, Inc. (“we,” “our,” “Protagenic” or “the Company”), formerly known as Atrinsic, Inc., is a Delaware corporation… |
| APEX-MOLECULAR-LTD |
APEX-MOLECULAR-LTD |
62%
|
anies such as Apex Molecular Ltd. to synthesize and purify these compounds for their pharmaceutical development programs. ● Acquisition of intellectual property from Alinova Biosciences Ltd. ● Contin… |
| BACKGROUND-PROTAGENIC-THERAPEUTICS-INC |
BACKGROUND-PROTAGENIC-THERAPEUTICS-INC |
62%
|
NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS Company Background Protagenic Therapeutics, Inc. (“we,” “our,” “Protagenic” or “the Company”), formerly known as Atrinsic, Inc., is a Delaware corporation… |
| BENCHMARK-INVESTMENTS-LLC |
BENCHMARK-INVESTMENTS-LLC |
62%
|
onths ended December 31, 2024 (as Phytanix Bio had only been incorporated in Nevada in 2024). By contrast, the combined company was conducting a level of R&D spending in the nine months ending Decemb… |
| B-RILEY-SECURITIES-INC |
B-RILEY-SECURITIES-INC |
62%
|
onths ended December 31, 2024 (as Phytanix Bio had only been incorporated in Nevada in 2024). By contrast, the combined company was conducting a level of R&D spending in the nine months ending Decemb… |
| EFFECTIVE-TIME-PROTAGENIC-THERAPEUTICS-INC |
EFFECTIVE-TIME-PROTAGENIC-THERAPEUTICS-INC |
62%
|
tstanding Preferred Shares of Phytanix Bio at the Effective Time, Protagenic Therapeutics, Inc. issued to the Preferred Stockholders, in accordance with their Preferred Pro Rata Portion, (A) an aggre… |
| FERVEN-LIMITED |
FERVEN-LIMITED |
62%
|
NOTE 1 – ORGANIZATION AND NATURE OF BUSINESS Company Background Protagenic Therapeutics, Inc. (“we,” “our,” “Protagenic” or “the Company”), formerly known as Atrinsic, Inc., is a Delaware corporation… |
| PHYTANIX-BIO-INC |
PHYTANIX-BIO-INC |
62%
|
any without the process of doing its own initial public offering, thereby affording it the opportunity to more quickly raise capital and provide liquidity options to its stockholders, and at the same… |
| PROTEIN-TECHNOLOGIES-LTD |
PROTEIN-TECHNOLOGIES-LTD |
62%
|
sured at the end of each reporting period. Income Taxes Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilitie… |
